Rezolute, INC

Rezolute, Inc. announced positive interim data from its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with 6 of 8 participants meeting the primary endpoint.

Rezolute, Inc. announced its third quarter fiscal 2026 financial results, detailing positive clinical data for its hyperinsulinism drug ersodetug and providing updates on ongoing studies.

Rezolute announced expanded analyses from its Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism, showing consistent glycemic improvements and high OLE participation.

Rezolute, Inc. announced outcomes from its recent Type B meeting with the FDA regarding its ersodetug program for congenital hyperinsulinism, where the FDA encouraged submission of comprehensive study data.

Rezolute, Inc. reported Q2 fiscal 2026 financial results and announced that its Phase 3 sunRIZE study for congenital hyperinsulinism did not meet primary or key secondary endpoints.

Rezolute, Inc. announced that its Phase 3 sunRIZE study for congenital hyperinsulinism did not meet primary or key secondary endpoints, while its Expanded Access Program for tumor hyperinsulinism showed compelling evidence of ersodetug activity.

Rezolute, Inc. filed its Q3 2026 Form 10-Q, detailing financial performance and operational updates, including the disappointing outcome of its Phase 3 sunRIZE trial for congenital hyperinsulinism.

Rezolute, Inc. reports its Phase 3 sunRIZE trial for congenital hyperinsulinism failed, leading to a workforce reduction and increased net losses, while the upLIFT trial for tumor HI progresses.

Rezolute, Inc. reported increased net losses and cash burn in its latest quarterly filing, while advancing two key Phase 3 clinical trials for its lead therapeutic, ersodetug.

Rezolute Inc. announces its Q3 2025 financial results and provides an update on its clinical development programs for ersodetug and RZ402, focusing on hyperinsulinism treatments.

Rezolute Inc. announces its financial results for the quarter ended December 31, 2024, and provides updates on its Phase 3 clinical trials for ersodetug in congenital and tumor hyperinsulinism.

Rezolute Inc. reports a net loss of $15.4 million for the quarter ended September 30, 2024, while advancing its clinical programs for hyperinsulinism and diabetic macular edema.

Rezolute, Inc. reports significant progress in its ersodetug clinical trials for hyperinsulinism, securing over $107 million in net proceeds from recent equity financings, despite ongoing net losses.

Rezolute, Inc.'s annual 10-K filing details the company's clinical advancements, financial status, and future plans, including progress in Phase 3 trials for its lead drug candidate.

Rezolute, Inc. Chief Medical Officer Brian Kenneth Roberts sold 3,062 common shares to cover tax withholding obligations related to Restricted Stock Units.

Rezolute Inc. CEO Nevan C. Elam reported a disposition of 8,004 common shares to cover tax withholding obligations related to RSU vesting.

Rezolute Inc. CFO Daron Evans reported a disposition of 3,062 common shares to cover tax withholding obligations related to RSU vesting.

Rezolute, Inc.'s CFO, Daron Evans, reported the direct acquisition of 10,000 common shares at $2.85 per share.

Rezolute's Chief Medical Officer, Brian Kenneth Roberts, disposed of 11,439 common shares to cover tax withholding obligations related to Restricted Stock Unit vesting.

Rezolute Inc.'s CFO, Daron Evans, disposed of 11,438 common shares to cover tax withholding obligations related to Restricted Stock Units vesting.

Rezolute, Inc. schedules its 2026 Annual Meeting of Stockholders for November 19, 2025, to vote on key proposals including director elections and an amendment to the equity incentive plan.

Rezolute, Inc. will hold its Annual Meeting of Stockholders virtually on December 5, 2024, to vote on director elections, auditor ratification, executive compensation, and amendments to the company's Articles of Incorporation and Stock Incentive Plan.

Rezolute, Inc. is holding its 2025 Annual Meeting of Stockholders on December 5, 2024, to vote on key proposals including the election of directors, ratification of the company's accountant, executive compensation, and an increase in authorized common stock.

Rezolute, Inc. is holding its 2024 Annual Meeting of Stockholders on May 16, 2024, to vote on key proposals including the election of directors, ratification of the company's accountant, executive compensation, and an amendment to the 2021 Incentive Compensation Plan.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5.28% of Rezolute, Inc. common stock as of March 31, 2026.

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, disclosing a combined beneficial ownership of 6.58% of Rezolute, Inc.'s common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in Rezolute Inc. common stock following an internal realignment.

A group of investors, including Invus Public Equities, L.P., has reported a complete divestment of their beneficial ownership in Rezolute, Inc. as of December 31, 2025.

Bank of America Corporation has reported a 6.5% beneficial ownership stake in Rezolute, Inc.'s common stock as of December 31, 2025.

The Vanguard Group has reported a 5.16% beneficial ownership stake in Rezolute Inc, holding 4,788,511 common shares as of December 31, 2025.